Effect of serum adropin levels on circulating endothelial dysfunction biomarkers in COVID-19 patients

Authors : Ramazan GÜNEŞAÇAR, Durkadın DEMİR EKŞİ, Ali Seydi ALPAY, Ferhat HANİKOĞLU, Haluk ERDOĞAN

Pages : 567-574

Doi:10.17826/cumj.1279322

View : 115 | Download : 172

Publication Date : 2023-07-02

Article Type : Research Paper

Abstract :Purpose: Several studies show that the symptoms of severe COVID-19 infection reflect the clinical phenotype of endothelial dysfunction and share common pathophysiological mechanisms with endothelial dysfunction. Therefore, the aim of the study was to investigate the effect of serum adropin levels on endothelial dysfunction biomarkers and determine whether adropin could be a new biomarker for COVID-19. Materials and Methods: The study included 40 patients with mild/moderate COVID-19, 48 patients with severe/critical COVID-19, and 37 controls. Serum adropin and circulating biomarkers of endothelial dysfunction including asymmetric dimethylarginine insert ignore into journalissuearticles values(ADMA);, endothelin-1 insert ignore into journalissuearticles values(ET-1);, endothelial nitric oxide synthase insert ignore into journalissuearticles values(eNOS);, soluble intercellular adhesion molecule-1 insert ignore into journalissuearticles values(sICAM-1); and plasminogen activator inhibitor-1 insert ignore into journalissuearticles values(PAI-1); levels were determined by micro-ELISA. Results: Serum adropin levels were found to be significantly higher in COVID-19 patients insert ignore into journalissuearticles values(165.2±11.49 pg/ml); than in controls insert ignore into journalissuearticles values(85.46±12.08 pg/ml);. Serum adropin levels of patients with severe/critical symptoms insert ignore into journalissuearticles values(194±16.23 pg/ml); were significantly higher than the patients with mild/moderate symptoms insert ignore into journalissuearticles values(130.6 ±14.53);. In addition, serum ADMA, eNOS, and, ET-1 levels were significantly higher in the COVID-19 subjects insert ignore into journalissuearticles values(150.5±8.67 ng/ml, 172.4±14.01 pg/ml, 159.3±10.19 pg/ml, respectively); than that those in the controls insert ignore into journalissuearticles values(104.5±9.182 ng/ml, 141.4±17.74 pg/ml, 100.1±11.37 pg/ml, respectively);. Significant positive correlations were found between adropin and ADMA, eNOS, ET-1, sICAM-1, and PAI-1 levels in the patients. Conclusion: We suggest that adropin may be a new potential biomarker for COVID-19 and an important molecule in restoring endothelial cell damage. Positive correlations between serum adropin levels and ADMA, eNOS, ET-1, sICAM-1 and PAI-1 levels in patients suggest that adropin may compensate for damage to endothelial cells.
Keywords : COVID 19, adropin, endotelyal disfonksiyon, biyobelirteçler

ORIGINAL ARTICLE URL